Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation

Comparative Medicine

Volumn 57, Issue 6, 2007, Pages 538-545

  Xie, Xiaobin ^a   Ramkumar, Vickram ^a   Toth, Linda A ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR; CAFFEINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR;

BRAIN DEPTH STIMULATION; CORPUS STRIATUM; ELECTROENCEPHALOGRAM; LOCOMOTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; REVIEW;

ADENOSINE; ANIMALS; BEHAVIOR, ANIMAL; CAFFEINE; CORPUS STRIATUM; DOPAMINE; HUMANS; LOCOMOTION; MODELS, BIOLOGICAL; PARKINSON DISEASE; PARKINSONIAN DISORDERS; RECEPTORS, DOPAMINE; RECEPTORS, PURINERGIC P1; RODENTIA; SIGNAL TRANSDUCTION;

EID: 38049064385     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Abbracchio MP, Colombo F, Di Luca M, Zaratin P, Cattabeni F. 1987. Adenosine modulates the dopaminergic function in the nigro-striatal system by interacting with striatal dopamine dependent adenylate cyclase. Pharmacol Res Commun 19:275-286.
2. Acquas E, Tanda G, Chiara G. 2002. Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine pretreated rats. Neuropsychopharmacology 27:182-193.
3. Ahlenius S, Salmi P. 1995. Antagonism of reserpine-induced suppression of spontaneous motor activity by stimulation of 5-HT1A receptors in rats. Pharmacol Toxicol 76:149-156.
4. Antoniou K, Papadopoulou-Daifoti Z, Hyphantis T, Papathanasiou G, Bekris E, Marselos M, Panlilio L, Muller CE, Goldberg SR, Ferre S. 2005. A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors. Psychopharmacol 183:154-162.
5. Aoyama S, Kase H, Borrelli H. 2000. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 20:5848-5852.
6. Ascherio A, Zhang SM, Hernan KA, Kawachi I, Colditz GA, Apeizer FE, Willett WC. 2001. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50:56-63.
7. Benoit-Marand M, Borrelli E, Gonon F. 2001. Inhibition of dopamine release via presynaptic D2 receptors: time course and functional characteristics in vivo. J Neurosci 21:9134-9141.
8. Bongiovanni R, Yamamoto BK, Simpson C, Jaskiw GE. 2003. Pharmacokinetics of systemically administered tyrosine: a comparison of serum, brain tissue and in vivo microdialysate levels in the rat. J Neurochem 67:310-317.
9. Borycz J, Pereira MF, Melani A, Rodrigues JR, Kofalvi A, Panlilio L, Pedata F, Goldberg SR, Cunha RA, Ferre S. 2007. Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments. J Neurochem 101:355-363.
10. Breuer O, Lawhorn C, Miller T, Smith DM, Brown LL. 2005. Functional architecture of the mammalian striatum: mouse vascular and striosome organization and their anatomic relationships. Neurosci Lett 385:198-203.
11. Brogden RN, Heel RC, Speight TM, Avery GS. 1981. alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use. Drugs 21:81-90.
12. Bruton RK, Ge J, Barnes NM. 1999. Group I mGlu receptor modulation of dopamine release in the rat striatum in vivo. Eur J Pharmacol 369:175-181.
13. Cass CE, Young JD, Baldwin SA. 1998. Recent advances in the molecular biology of nucleoside transporters of mammalian cells. Biochem Cell Biol 76:761-770.
14. Cauli O, Morelli M. 2002. Subchronic caffeine administration sensitizes rats to the motor-activating effects of dopamine D(1) and D(2) receptor agonists. Psychopharmacol 162:246-254.
15. Chen JF, Beilstein M, Xu YH, Turner TJ, Moratella R, Standaert DG, Aloyo VJ, Fink JS, Schwarzschild MA. 2000. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience 97:195-204.
16. Corvol JC, Studler JM, Schonn JS, Girault JA, Herve D. 2001. Galpha(olf) is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum. J Neurochem 76:1585-1588.
17. Cunha RA, Johansson B, van der Ploeg I, Sebastiao AM, Ribeiro JA, Fredholm BB. 1994. Evidence for functionally important adenosine A2A receptors in the rat hippocampus. Brain Res 694:208-216.
18. Dassesse D, Vanderwinden JM, Goldberg I, Vanderhaegen JJ, Schiffmann SN. 1999. Caffeine-mediated induction of cfos, zif-268 and arc expression through A1 receptors in the striatum: different interactions with the dopaminergic system. Eur J Neurosci 11:3101-3114.
19. Deleu D, Jacob P, Chand P, Sarre S, Colwell A. 2006. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Neurology 67:897-899.
20. Dunwiddie TV, Diao LH. 1994. Extracellular adenosine in hippocampal brain slices and the tonic inhibitory modulation of evoked excitatory responses. J Pharmacol Exp Ther 268:537-545.
21. Dunwiddie TV, Masino SA. 2001. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 24:31-55.
22. El Yacoubi M, Ledent C, Menard JF, Parmentier M, Costentin J, Vaugeois JM. 2000. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A2A receptors. Br J Pharmacol 129:1465-1473.
23. El Yacoubi M, Ledent C, Parmentier M, Costentin J, Vaugeois JM. 2003. Caffeine reduces hypnotic effects of alcohol through adenosine A2A receptor blockade. Neuropharmacology 45:977-985.
24. Feoktistov I, Biaggioni I. 1997. Adenosine A2B receptors. Pharmacol Rev 49:381-402.
25. Ferre S, Agnati LF, Ciruela F, Lluis C, Woods AS, Fuxe K, Franco R. 2007. Neurotransmitter receptor heteromers and their integrative role in 'local modules': the striatal spine module. Brain Res Rev Forthcoming.
26. Ferre S, Snaprud P, Fuxe K. 1993. Opposing actions of an adenosine A2 agonist and a GTP analogue on the regulation of dopamine D2 receptors in rat neostriatal membranes. Eur J Pharmacol 244:311-315.
27. Ferre S, Torvinen M, Antoniou K, Irenius E, Civelli O, Arenas E, Fredholm BB, Fuxe K. 1998. Adenosine A1 receptor-mediated modulation of dopamine D1 receptors in stably cotransfected fibroblast cells. J Biol Chem 273:4718-4724.
28. Fink JS, Weaver DR, Rivkees SA, Peterfreund RA, Pollack AE, Adler EM, Reppert SM. 1992. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptor in rat striatum. Mol Brain Res 14:186-195.
29. Fredholm BB, Bättig K, Holmen J, Nehlig A, Zvartau EE. 1999. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83-133.
30. Garrett BE, Holtzman SG. 1994. Caffeine cross-tolerance to selective dopamine D1 and D2 receptor agonists but not to their synergistic interaction. Eur J Pharmacol 262:65-75.
31. Gasior M, Jaszyna M, Peters J, Goldberg SR. 2000. Changes in the ambulatory activity and discriminative stimulus effects of psycho-stimulant drugs in rats chronically exposed to caffeine: effect of caffeine dose. J Pharmacol Exp Ther 295:1101-1111.
32. Gerfen CR. 1992. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 15:285-320.
33. Gonon FG. 1988. Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 24:19-28.
34. Grillner S, Hellgren J, Menard A, Saitoh E, Wikstrom MA. 2005. Mechanisms for selection of basic motor programs- roles for the striatum and pallidum. Trends Neurosci 28:364-370.
35. Halldner L, Lozza G, Lindstrom K, Fredholm BB. 2000. Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist. Eur J Pharmacol 406:345-354.
36. Hettinger BD, Lee A, Linden J, Rosin DL. 2001. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 431:331-346.
37. Hirotsu I, Horikawa Y, Kihara T, Ishihara T, Kanai T. 1992. Reversal of alpha-methyltyrosine-induced hypoactivity by 6-(R)-5,6,7,8- tetrahydro-L-erythrobiopterin (R-THBP) in mice. Jpn J Pharmacol 58:67-73.
38. Jaber M, Robinson SW, Missale C, Caron MG. 1996. Dopamine receptors and brain function. Neuropharmacology 35:1503-1519.
39. Jiang Q, Van Rhee AM, Kim J, Yelhe S, Wess J, Jacobson KA. 1996. Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. Mol Pharmacol 50:512-521.
40. Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, Gimenez-Llort L, Escorihuela RM, Fernandex-Teruel A, Wiesenfeld-Hallin Z, Xu XJ, Hardemark A, Betsholtz C, Herlenius E, Fredholm BB. 2001. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Nat Acad Sci USA 98:9407-9412.
41. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P. 2000. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162:321-317.
42. Karcz-Kubicha M, Antoniou K, Terasmaa A, Quata D, Solinas M, Justinova Z, Pezzola A, Reggio R, Muller CE, Fuxe K, Goldberg SR, Popoli P, Ferre S. 2003. Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 28:1281-1291.
43. Kaushik P, Gorin F, Vali S. 2007. Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis. J Comput Neurosci 22:147-160.
44. Kumer SC, Vrana KE. 1996. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 67:443-462.
45. Ledent C, Vaugeois JM, Schiffman SE, Pedrazzini T, El Yacoubi M, Vanderhaegen JJ. 1997. Aggressiveness, hypoalgesia and increased blood pressure in mice deficient for the adenosine A2a receptor. Nature 388:674-678.
46. Lindgren N, Xu ZG, Herrara-Marschitz M, Haycock J, Hokfelt T, Fisone G. 2001. Dopamine D2 receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum. Eur J Neurosci 13:773-780.
47. Lindskog M, Svenningsson P, Pozzi L, Kim Y, Fienberg AA, Bibb JA, Fredholm BB, Nairn AC, Greengard P, Fisone G. 2002. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature 418:774-778.
48. Lloyd HG, Fredholm BB. 1995. Involvement of adenosine deaminase and adenosine kinase in regulating extracellular adenosine concentration in hippocampal slices. J Neurochem 26:387-395.
49. Marchi M, Raiteri L, Risso F, Vallarino A, Bonfanti A, Monopoli A, Ongini E, Raiteri M. 2002. Effects of adenosine A1 and adenosine A2A receptor activation on the evoked release of glutamate from cerebrocortical synaptosomes. Br J Pharmacol 136:434-440.
50. Matsuya T, Takuma K, Sato K, Asai M, Murakami Y, Miyoshi S, Noda A, Nagai T, Mizoguchi H, Nihimura S, Yamada K. 2007. Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model. J Pharmacol Sci 103:329-332.
51. Mayfield RD, Zahniser NR. 2001. Dopamine D2 receptor regulation of the dopamine transporter expressed in Xenopus laevis oocytes is voltage-independent. Mol Pharmacol 59:113-121.
52. Missale C, Nash CR, Robinson SW, Jaber M, Caron MG. 1998. Dopamine receptors: from structure to function. Physiol Rev 78:189-225.
53. Nagel J, Schladebach H, Koch M, Schweinbacher I, Muller CE, Hauber W. 2003. Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. Synapse 49:279-286.
54. Okada M, Mizuno K, Kaneko S. 1996. Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci Lett 212:53-56.
55. Parent A, Sato F, Wu Y, Gauthier J, Levesque M, Parent M. 2000. Organization of the basal ganglia: the importance of axonal collateralization. Trends Neurosci 23 (Suppl):S20-S27.
56. Park J, Singh B, Gupta RS. 2006. Inhibition of adenosine kinase by phosphonate and bisphosphonate derivatives. Mol Cell Biochem 283:11-21.
57. Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB. 2006. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther 319:237-246.
58. Pedata F, Corsi C, Melani A, Bordoni F, Latini S. 2001. Adenosine extracellular brain concentrations and role of A2A receptors in ischemia. Ann N Y Acad Sci 939:74-84.
59. Popoli P, Reggio R, Pezzola A. 2000. Effects of SCH 58261, an adenosine A(2A) receptor antagonist, on quinpirole-induced turning in 6-hydroxydopamine-lesioned rats: lack of tolerance after chronic caffeine intake. Neuropsychopharmacology 22:522-529.
60. Quarta D, Borycz J, Solinas M, Patkar K, Hockemeyer J, Ciruela F, Lluis C, Franco R, Woods AS, Goldberg SR, Ferre S. 2004. Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and Nmethyl-D-aspartate receptor stimulation. J Neurochem 91:873-880.
61. Rainnie DG, Grunze HC, McCarley RW, Greene RW. 1994. Adenosine inhibition of mesopontine cholinergic neurons: implications for EEG arousal. Science 263:689-692.
62. Ralph RJ, Caine SB. 2005. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. J Pharmacol Exp Ther 312:733-741.
63. Rivkees SA, Price SL, Zhou FC. 1995. Immunohistochemical detection of A1 adenosine receptors in rat brain with emphasis on localization in the hippocampal formation, cerebral cortex, cerebellum and basal ganglia. Brain Res 677:193-203.
64. Rosin DL, Hettinger BD, Lee A. 2003. Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function. Neurology 61:S12-S18.
65. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR. 2000. Association of coffee and caffeine intake with the risk of Parkinson disease. J Am Med Assoc 283:2674-2679.
66. Roth RH. 1984. CNS dopamine autoreceptors: distribution, pharmacology and function. Ann N Y Acad Sci 430:27-53.
67. Sahin B, Galdi S, Hendrick J, Greene RW, Snyder GL, Bibb JA. 2007. Evaluation of neuronal phosphoproteins as effectors of caffeine and mediators of striatal adenosine A2A receptor signaling. Brain Res 1129:1-14.
68. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. 2006. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 29:647-654.
69. Sladek JR, Elsworth JD, Roth RH, Evans LE, Collier TJ, Cooper SJ, Taylor JR, Redmond DE. 1993. Fetal dopamine cell survival after transplantation is dramatically improved at a critical donor gestational age in nonhuman primates. Exp Neurol 122:16-27.
70. Smeets WJ, Marin O, Gonzalez A. 2000. Evolution of the basal ganglia: new perspectives through a comparative approach. J Anat 196 (Pt 4):501-517.
71. Solinas M, Ferre S, Antoniou K, Quarta D, Justinova Z, Hockemeyer J, Pappas LA, Segal PN, Werthein C, Muller CE, Goldberg SR. 2005. Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats. Psychopharmacol 179:576-586.
72. Solinas M, Ferre S, You ZB, Karcz-Kubicha M, Popoli P, Goldberg SR. 2002. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci 22:6321-6324.
73. Stoof JC, Kebabian JW. 1981. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294:366-368.
74. Svenningsson P, Nomikos GG, Fredholm BB. 1995. Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration. J Neurosci 15:7612-7624.
75. Tolwani RJ, Jakowec MW, Petinger GM, Green SL, Waggie K. 1999. Experimental models of Parkinson's disease: insights from many models. Lab Anim Sci 49:363-371.
76. van Meer P, Raber J. 2005. Mouse behavioral analysis in systems biology. Biochem J 389:593-610.
77. Waddington JL, O'Boyle KM. 1989. Drugs acting on brain dopamine receptors', a conceptual reevaluation five years after the first selective Dl antagonist. Pharmacol Ther 43:1-52.
78. Wolf ME, Roth RH. 1990. Autoreceptor regulation of dopamine synthesis. Ann N Y Acad Sci 604:323-343.
79. Wu WP, Hao JX, Halldner L, Lovdahl C, DeLander GE, Wiesenfeld-Hallin Z, Fredholm BB, Xu XJ. 2005. Increased nociceptive response in mice lacking the adenosine A1 receptor. Pain 113:395-404.
80. Wu WP, Hao JX, Halldner-Henriksson L, Xu XJ, Jacobson MA, Wiesenfeld-Hallin Z, Fredholm BB. 2002. Decreased inflammatory pain due to reduced carrageenan-induced inflammation in mice lacking adenosine A3 receptors. Neurosci 114:523-527.
81. Xu K, Bastia E, Schwarzschild M. 2005. Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease. Pharmacol Ther 105:267-310.
82. Yaar R, Jones MR, Chen JF, Ravid K. 2005. Animal models for the study of adenosine receptor function. J Cell Physiol 101:9-20.